WallStreetZenWallStreetZen

NASDAQ: SNY
Sanofi Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

SNY past earnings growth

How has SNY's earnings growth performed historically?
Company
-32.73%
Industry
0.14%
Market
61.16%
SNY's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
SNY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
SNY's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

SNY past revenue growth

How has SNY's revenue growth performed historically?
Company
6.87%
Industry
4.62%
Market
16.96%
SNY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SNY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SNY's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SNY earnings and revenue history

Current Revenue
$51.6B
Current Earnings
$6.0B
Current Profit Margin
11.6%
SNY's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

SNY Return on Equity

Current Company
7.3%
Current Industry
34.1%
Current Market
188%
SNY's Return on Equity (7.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SNY announces earnings.

SNY Return on Assets

Current Company
4.3%
Current Industry
8.3%
SNY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SNY Return on Capital Employed

Current Company
8.13%
Current Industry
14.8%
SNY's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SNY vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SNY$49.94B$14.09B$5.81B+4.70%+3.84%
BMY$45.01B$18.19B$8.03B+14.81%+5.21%
AMGN$28.19B$14.80B$6.72B+3.49%-0.22%
PFE$58.50B$7.29B$2.12B+7.46%-27.52%
GILD$27.12B$10.55B$5.67B+4.15%+1.57%
View Top General Drug Manufacturer Stocks

Sanofi Earnings & Revenue FAQ

What were SNY's earnings last quarter?

On Invalid Date, Sanofi (NASDAQ: SNY) reported Q4 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Sanofi earnings for the quarter were N/A. In the same quarter last year, Sanofi's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Sanofi stock.

What was SNY's earnings growth in the past year?

As of Q2 2024, Sanofi's earnings has grown -32.73% year over year. This is 32.87 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 0.14%. Sanofi's earnings in the past year totalled $5.81 billion.

What was SNY's revenue last quarter?

On Invalid Date, Sanofi (NASDAQ: SNY) reported Q4 2023 revenue of N/A up N/A year over year. In the same quarter last year, Sanofi's revenue was N/A.

What was SNY's revenue growth in the past year?

As of Q2 2024, Sanofi's revenue has grown 6.87% year over year. This is 2.25 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 4.62%. Sanofi's revenue in the past year totalled $49.94 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.